Article in RSC advances, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 0 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors at 2 institutions in 1 country.
Vitor Tassara MoraesDepartamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil gclososki@usp.br +55 16 3315-4208.ORCID https://orcid.org/0000-0003-0126-895X
Franco Jazon CairesDepartamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil gclososki@usp.br +55 16 3315-4208.ORCID https://orcid.org/0000-0002-4579-6837
Pedro V da Silva-NetoDepartamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto-FFCLRP, Universidade de São Paulo-USP Ribeirão Preto 14040-901 SP Brazil.ORCID https://orcid.org/0000-0003-1209-9346
Jacqueline Nakau MendonçaDepartamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil gclososki@usp.br +55 16 3315-4208.ORCID https://orcid.org/0000-0003-0558-0430
Thais F C Fraga-SilvaInstituto de Ciências Biológicas e da Saúde, Universidade Federal de Alagoas-UFAL Maceió 57072-900 AL Brazil.ORCID https://orcid.org/0000-0002-2053-8938
Bianca Bueno FontaneziDepartamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil.ORCID https://orcid.org/0000-0002-5439-6579
Priscyla Daniely MarcatoDepartamento de Ciências Farmacêuticas, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil.ORCID https://orcid.org/0000-0003-0378-9580
Vania Luiza Deperon BonatoDepartamento de Bioquímica e Imunologia, Faculdade de Medicina de Ribeirão Preto-FMRP, Universidade de São Paulo-USP Ribeirão Preto 14040-900 SP Brazil.ORCID https://orcid.org/0000-0003-4189-2685
Carlos Arterio SorgiDepartamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto-FFCLRP, Universidade de São Paulo-USP Ribeirão Preto 14040-901 SP Brazil.ORCID https://orcid.org/0000-0001-7528-9935
Luiz Alberto Beraldo MoraesDepartamento de Química, Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto-FFCLRP, Universidade de São Paulo-USP Ribeirão Preto 14040-901 SP Brazil.ORCID https://orcid.org/0000-0002-0853-1944
Giuliano Cesar ClososkiDepartamento de Ciências Biomoleculares, Faculdade de Ciências Farmacêuticas de Ribeirão Preto, Universidade de São Paulo-USP Ribeirão Preto 14040-903 SP Brazil gclososki@usp.br +55 16 3315-4208.ORCID https://orcid.org/0000-0001-7605-4150
Universidade de Ribeirão Preto · BRUniversidade de São Paulo · BR
Funding
No grant is acknowledged in the PubMed record.
6 · The paper itself
Abstract
Inflammation plays a crucial role in COVID-19, and when it becomes dysregulated, it can lead to severe outcomes, including death. Naphthoquinones, a class of cyclic organic compounds widely distributed in nature, have attracted significant interest due to their potential biological benefits. One such naphthoquinone is 3,5,8-trihydroxy-6-methoxy-2-(5-oxohexa-1,3-dienyl)-naphthanthene-1,4-dione (3,5,8-TMON), a compound produced by fungi. Despite its structural similarity to shikonin, limited research has been conducted to investigate its biological properties. Therefore, the objective of this study was to evaluate the effects of 3,5,8-TMON and its synthetic derivatives in the context of inflammation induced by lipopolysaccharide (LPS) and SARS-CoV-2 infection
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Naphthoquinone derivatives as potential immunomodulators: prospective for COVID-19 treatment. · full record | OpenQuestion